Immunotherapeutic and Targeted Approaches in Multiple Myeloma

The multiple myeloma (MM) therapeutic landscape has evolved significantly with the approval of numerous novel agents, including next generation proteasome inhibitors (PIs), immunomodulatory agents (IMIDs), and monoclonal antibodies (MoABs) targeting CD38 and SLAMF7. While these discoveries have led...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadeem, Omar, Tai, Yu-Tzu, Anderson, Kenneth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569026/
https://www.ncbi.nlm.nih.gov/pubmed/33117743
http://dx.doi.org/10.2147/ITT.S240886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569026/
https://www.ncbi.nlm.nih.gov/pubmed/33117743
http://dx.doi.org/10.2147/ITT.S240886

Ejemplares similares